Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)
Phase of Trial: Phase IV
Latest Information Update: 01 May 2015
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms Perseas
- Sponsors Roche
- 15 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Aug 2012 Actual end date changed from 1 Mar 2010 to 1 May 2009 as reported by ClinicalTrials.gov.
- 15 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.